Abstract
Using the patch clamp technique we investigated the effects of the centrally acting muscle relaxant chlorzoxazone and three structurally related compounds, 1-ethyl-2-benzimidazolinone (1-EBIO), zoxazolamine, and 1,3-dihydro-1-[2-hydroxy-5-(triflu oromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one (NS 1619) on recombinant rat brain SK2 channels (rSK2 channels) expressed in HEK293 mammalian cells. SK channels are small conductance K+ channels normally activated by a rise in intracellular Ca2+ concentration; they modulate the electrical excitability in neurons and neuroendocrine cells. When applied externally, chlorzoxazone, 1-EBIO, and zoxazolamine activated rSK2 channel currents in cells dialyzed with a nominally Ca2+-free intracellular solution. The activation was reversible, reproducible, and depended on the chemical structure and concentration. The order of potency was 1-EBIO > chlorzoxazone > zoxazolamine. Activation of rSK2 channels by chlorzoxazone, 1-EBIO, and zoxazolamine declined at higher drug concentrations. Zoxazolamine, when applied in combination with chlorzoxazone or 1-EBIO, partially inhibited the rSK2 channel current responses, suggesting a partial-agonist mode of action. 1-EBIO failed to activate rSK2 channel currents when applied to excised inside-out membrane patches exposed to a Ca2+-free intracellular solution. In contrast, 1-EBIO activated rSK2 currents in a concentration-dependent manner when coapplied to the patches with a solution containing 20 nM free Ca2+. NS 1619 did not activate rSK2 channel currents; it inhibited rSK2 channel currents activated by the other three test compounds or by high intracellular Ca2+. We conclude that chlorzoxazone and its derivatives act through a common mechanism to modulate rSK2 channels, and SK channel modulation in the brain may partly underlie the clinical effects of chlorzoxazone.
Footnotes
-
Send reprint requests to: Khaled M. Houamed, Ph.D., Department of Anesthesia and Critical Care, University of Chicago, 5841 S. Maryland Ave., Box 4028, Chicago, IL 60637. E-mail:khouamed{at}midway.uchicago.edu
-
This work was funded in part by grants from the Brain Research Foundation, the Diabetes Research and Training Center, The University of Chicago, the Whitehall Foundation, and the American Heart Association, Midwest Affiliate.
- Abbreviations:
- SK channels
- small conductance calcium-activated potassium channels
- BK channels
- large conductance calcium-activated potassium channels
- IK channels
- intermediate conductance calcium-activated potassium channels
- rSK2 channels
- rat brain-derived recombinant SK2 channels
- BAPTA
- 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid
- 1-EBIO
- 1-ethyl-2-benzimidazolinone
- HEDTA
- N-(2-hydroxyethyl)ethylenediamine-N,N′,N′-triacetic acid
- HEK293
- human embryonic kidney 293 cells
- NS 1619
- 1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one
- IV
- current-voltage
- pA
- picoampere
- pF
- picofarad
- nA
- nanoampere
- Received September 13, 2000.
- Accepted November 30, 2000.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|